Latest News and Press Releases

LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of...

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term...

No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to be...

YPrime earns prestigious EcoVadis rating, reinforcing commitment to sustainable clinical research.

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

YPrime launches eCOA Automated Data Change Form, reimagining clinical trial data management with enhanced efficiency and accuracy.

Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...

Austin, TX, USA, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Clinical Trial Outsourcing Market Size, Trends and Insights By Services...

YPrime's Dr. Karl McEvoy, VP eCOA & Patient Technologies, has been appointed Industry Co-Director of the Critical Path Institute (C-Path) eCOA Consortium